THIS WEBSITE USES COOKIES

We use cookies to personalize content and ads, provide social media features, and analyze traffic to our website. We also share information about your use of our website with our social media, advertising and analytics partners. Our partners may combine this information with other data that you have provided to them or that they have collected in the course of your use of the Services.

NOVO NORDISK A/S

Photo credits: pixabay.com

Commented by Stefan Feulner on October 16th, 2023 | 06:50 CEST

Lots of activity in the biotech sector - Novo Nordisk, Defence Therapeutics, Morphosys

Biotechnology
Pharma
Innovations

Despite the rather gloomy economic outlook on the one hand and high interest rates on the other, there is significant movement in the capital-intensive biotechnology sector. After Amgen successfully concluded the acquisition of Horizon Therapeutics for USD 116.50 per share or a total volume of around USD 27.8 billion, further investments by Big Pharma in innovative and promising technologies will likely follow soon.

Read